Cancer experts point to new advances in research and treatment: A recent report by the American Association for Cancer Research highlights unprecedented successes as well as ongoing challenges in the cancer field

FDA, AACR, immunotherapeutics, immunotherapy, precision therapies, ALK, EGFR, BRAF

Within the last few years, cancer research has made significant strides, leading to the approval of 22 new cancer treatments by the FDA between August 1, 2017, and July 31, 2018. Among these, notable advancements include 14 anticancer therapeutics, such as CAR T-cell therapies for non-Hodgkin lympho…

Apr 1^st • 2 mins read

Loose Regulatory Standards Portend a New Era of Imprecision Oncology

precision oncology, TMB-high, homologous recombination deficiency, Olaparib, pembrolizumab

Precision oncology aims to tailor cancer treatment based on genetic understanding, revolutionizing oncology. The FDA has been approving drugs under precision oncology with broad indications that may not align with studied populations. Examples include the approval of pembrolizumab for a wide ran…

Dec 1^st • 4 mins read

Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis

Health Outcomes and Economics of Cancer Care, Lung Cancer, NSCLC, EMA

Treatment for non-small cell lung cancer (NSCLC) has significantly improved with the introduction of targeted and immune-oncologic drugs. Despite rapid development and European Medicinal Agency (EMA) registration, these novel drugs are not easily accessible in Central and Eastern European (CEE) c…

Nov 24^th • 10 mins read